<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01589146</url>
  </required_header>
  <id_info>
    <org_study_id>Unipg-CRU-01-2012</org_study_id>
    <nct_id>NCT01589146</nct_id>
  </id_info>
  <brief_title>ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER.</brief_title>
  <acronym>PRO-LAPS I</acronym>
  <official_title>ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS IN PATIENTS WITH COLORECTAL CANCER UNDERGOING LAPAROSCOPIC SURGERY: INCIDENCE OF VENOUS THROMBOEMBOLISM AND BLEEDING COMPLICATIONS. THE PRO-LAPS STUDY.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overall, only limited evidence exists regarding the clinical benefit of antithrombotic
      prophylaxis after laparoscopic surgery for cancer. Four studies reported on the incidence of
      venous thromboembolism (VTE) after laparoscopic surgery for cancer. These studies differ
      concerning study design, site of cancer, regimens for antithrombotic prophylaxis and reported
      incidence of VTE.

      The aim of this multicenter, randomized study is to assess the clinical benefit of extended
      (4 weeks) compared to short (one week) heparin prophylaxis after laparoscopic surgery for
      colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>symptomatic objectively confirmed VTE, asymptomatic ultrasonography-confirmed DVT or VTE-related death</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>The Primary Study Objective is to Assess the Efficacy and</condition>
  <condition>Safety of Extended 4-week Heparin Prophylaxis Compared to</condition>
  <condition>Prophylaxis Given for 8Â±2 Days After Planned Laparoscopic</condition>
  <condition>Surgery for Colorectal Cancer.</condition>
  <condition>The Clinical Benefit Will be Evaluated as the Difference in</condition>
  <condition>the Incidence of VTE or VTE-related Death Occurring Within 30 Days</condition>
  <condition>From Surgery in the Two Study Groups.</condition>
  <arm_group>
    <arm_group_label>short heparin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>extended heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin, Low-Molecular-Weight</intervention_name>
    <description>4 weeks heparin prophylaxis</description>
    <arm_group_label>extended heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients who had

          -  planned laparoscopic surgery for

          -  colorectal cancer will be included in the study provided no exclusion criteria will be
             found

        Exclusion Criteria:

          -  age &lt; 18 years

          -  surgery for non-cancer disease

          -  duration of surgery &lt; 45 min

          -  other indication for anticoagulant therapy

          -  known cerebral metastases

          -  kidney or liver failure

          -  known hemorrhagic diathesis or high risk for bleeding

          -  history of intracerebral bleeding or neurosurgery within 6 months, history of heparin
             induced thrombocytopenia

          -  pregnancy or lactation

          -  refusal of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cecilia Becattini</last_name>
    <phone>+39 075 5786424</phone>
    <email>cecilia.becattini@unipg.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Internal and Cardiovascular Medicine - University of Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2012</study_first_submitted>
  <study_first_submitted_qc>April 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2012</study_first_posted>
  <last_update_submitted>April 28, 2012</last_update_submitted>
  <last_update_submitted_qc>April 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Cecilia Becattini</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>colon-rectal cancer</keyword>
  <keyword>heparin</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>laparoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

